Méhnyakrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MYC 0
• MAPK 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

2705 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Cervical Cancers Escaping HPV Screening: Decoding HPV-Independent Carcinogenesis through Multi-Omics Profiling (ESCAPE-HPV)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 1 493 450 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-RIA

  Offering combined HPV vaccination and HPV test-based cervical screening to vulnerable populations. A hybrid efficacy and implementation study. (HPV-FASTER-Implement)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 6 602 445 EUR· until 2029. dec.· 8 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Understanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa. (IMPROVE-HPV)

  Institut Catala D'oncologia· Hospitalet de Llobregat, Spanyolország· EU contribution 3 613 288 EUR· until 2028. máj.· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineering B cells to fight cancer (EngineerBcells)

  Tel Aviv University· Tel Aviv, Izrael· EU contribution 1 996 250 EUR· until 2027. szept.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training. (DUALSAVE-FGS)

  Oslo Universitetssykehus Hf· Oslo, Norvégia· EU contribution 7 984 441 EUR· until 2027. aug.· 6 countries

5 of 6 running projects, newest first. Listed amounts together: 23,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

  NCT05337735· M.D. Anderson Cancer Center· Frissítve: 2026. okt. 13.

  “PI Request”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer

  NCT03634267· M.D. Anderson Cancer Center· Frissítve: 2026. szept. 15.

  “PI Request”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

  NCT04630353· AstraZeneca· Frissítve: 2026. szept. 14.

  “Sponsor decision.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

  NCT07181720· Chongqing Precision Biotech Co., Ltd· Frissítve: 2026. szept. 11.

  “Sponsor stopped the study.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Impact of Basic Needs Assessment and Support to Improve Colposcopy Show Rate

  NCT05458960· Washington University School of Medicine· Frissítve: 2026. aug. 31.

  “Staffing issues”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV

  NCT07090174· University of California, San Diego· Frissítve: 2026. aug. 19.

  “Study withdrawn prior to participant enrollment due to lack of study product.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Paclitaxel Therapeutic Drug Monitoring in Cancer Patients

  NCT03987555· Wake Forest University Health Sciences· Frissítve: 2026. aug. 13.

  “Funding”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

  NCT05572684· NextCure, Inc.· Frissítve: 2026. aug. 13.

  “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

  NCT04974944· Sun Yat-Sen University Cancer Center· Frissítve: 2026. júl. 29.

  “No superior PFS in study group among the enrolled patients. Company R\&D strategy shifted; funding discontinued, study terminated.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

  NCT06022757· Evopoint Biosciences Inc.· Frissítve: 2026. júl. 23.

  “Strategic decision by Sponsor.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

  NCT04491942· National Cancer Institute (NCI)· Forrás

• Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors

  NCT06660654· Daiichi Sankyo Inc.· Forrás

• SCREEN Yourself for Cancer

  NCT07927686· Milton S. Hershey Medical Center· Forrás

• Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

  NCT06079671· AstraZeneca· Forrás

• High-risk HPV Testing With Pap Smear Triage for Cervical Cancer Screening in Women Aged 50 and Older in Ethiopia

  NCT07929246· University Medical Center Groningen· Forrás

• A Cervical Cancer Prevention Program in Kenya

  NCT06411938· Indiana University· Forrás

• Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· National Cancer Institute (NCI)· Forrás

• Developing a Gynecologic Cancer Health Promotion Community Engagement Program

  NCT07910162· Abramson Cancer Center at Penn Medicine· Forrás

• A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

  NCT06459180· Merck Sharp & Dohme LLC· Forrás

• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Merck Sharp & Dohme LLC· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 21
• Gene Expression Profiling 70
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 18
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 66
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 63
• Deep Learning 50
• Cohort Studies 82
• Genome-Wide Association Study 14

• Multi-omics profiling reveals sphingolipid metabolism reprogramming of tumor-conditioned MDSCs in cervical cancer.

  BMC Cancer, 2026. szept.

• Multi-omics analysis reveals the alterations in the tumor microbiome and metabolome associated with cervical cancer lymph node metastasis.

  Microbiol Spectr, 2026. ápr.

• Integrated spatial multi-omics delineates fatty acid degradation fuels malignant evolution at the tumour periphery in cervical squamous cell carcinoma.

  EBioMedicine, 2026. ápr.

• Integrated cross-sectional study and functional validation indicate the association of lactobacillus crispatus-derived D-lactic acid with cervical gene expression and precancerous cervical lesions.

  J Transl Med, 2026. márc.

• From seed to bioactive: unveiling sprouting-driven changes in chickpeas via targeted metabolomics and in silico modelling.

  J Chromatogr B Analyt Technol Biomed Life Sci, 2025. dec.

• Protocol for investigating mitochondrial structure, function, and metabolism in human cervical cancer cells.

  STAR Protoc, 2025. nov.

• Spatial multi-omics guides ASCT2-targeted delivery of glycolysis inhibitor for cervical cancer suppression and chemoresistance reversal.

  J Adv Res, 2025. nov.

• Metabolomics and proteomics reveal the inhibitory effect of Lactobacillus crispatus on cervical cancer.

  Talanta, 2024. szept.

• Association of Plasma Selenium and Its Untargeted Metabolomic Profiling with Cervical Cancer Prognosis.

  Biol Trace Elem Res, 2023. jan.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.